Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab for allergen-induced asthma responses
ACTRN12614000123640Phase 2Completed
- Sponsor
- QIMR Berghofer Medical Research Institute
- Start
- Oct 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in asthma and allergic asthma comparing Tocilizumab with Placebo (2 arms). Primary endpoints: Late asthmatic response and Safety laboratory assessments. Started Oct 2014; status: completed.
02
Drugs
tocilizumab
03
Conditions
asthmaallergic asthma
Beyond the preview
Go deeper on ACTRN12614000123640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12614000123640.